Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02392325 · ClinicalTrials.gov registry record · Phase 1

Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults

A Phase 1 study of Dengue, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
Phase 1
Development phase
12
Enrollment target
1
Study location

NCT02392325: Completed Phase 1 study of Dengue, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT02392325 is a Phase 1 study of Dengue that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 12 participants, below the 3,980-participant average among 9 other Dengue trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02392325, a Phase 1 study of Dengue, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
Phase 1
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

Dengue viruses infect millions of people throughout the tropics and subtropics each year. The development of a dengue vaccine is an important health priority. This study will evaluate the immunologic and clinical response to two dengue vaccines, given 9 months apart, in healthy adults with no history of previous flavivirus infection.

Conditions Studied

Dengue

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL rDEN1Δ30
  • BIOLOGICAL rDEN2Δ30-7169

Study Locations (1)

Maryland

  • Center for Immunization Research, Johns Hopkins School of Public Health - Baltimore

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2015-03
Est. Completion 2017-02
Phase Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

What the finished NCT02392325 record still lists

NCT02392325 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 3,980-participant average among 9 other Dengue trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Dengue appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT02392325 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT02392325 about?

NCT02392325 is a clinical study titled "Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults". Dengue viruses infect millions of people throughout the tropics and subtropics each year. The development of a dengue vaccine is an important health priority. This study will evaluate the immunologic and clinical response to two dengue vaccines, given 9 months apart, in healthy adults with no histor...

What is the current status of trial NCT02392325?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2015-03. Estimated completion is 2017-02.

What conditions does trial NCT02392325 study?

This clinical trial studies the following conditions: Dengue.

What interventions are being tested in trial NCT02392325?

The interventions under investigation include: Placebo (BIOLOGICAL), rDEN1Δ30 (BIOLOGICAL), rDEN2Δ30-7169 (BIOLOGICAL).

Who is sponsoring clinical trial NCT02392325?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02392325 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Dengue

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02392325's enrollment target sits among peer trials

12 9th of 9 higher than 1 of 9 other Dengue trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Dengue trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02392325, the US trial registry maintained by the National Library of Medicine. NCT02392325 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.